Posted by Michael Wonder on 17 Oct 2020
ICER publishes evidence report on therapies for haemophilia A
16 October 2020 - Emicizumab assessed as providing comparable or better clinical benefits when compared to common current dosing levels of prophylactic factor VIII; it is also cost saving but only because factor VIII prices are extremely high and have not moderated with competition.
The Institute for Clinical and Economic Review (ICER) today released an Evidence Report assessing the comparative clinical effectiveness and value of valoctocogene roxaparvovec (Roctavian, BioMarin Pharmaceutical) and emicizumab (Hemlibra, Genentech) for the treatment of haemophilia A.
